Want to see INDP full AI Analyst Report?
Top Page
Indaptus Therapeutics
(NASDAQ:INDP)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.00
▼(-61.69% Downside)
Action:Reiterated
Date:08/17/26
The score is held down primarily by weak financial performance (pre-revenue, sustained losses, and ongoing cash burn) and bearish technical trends (price below key moving averages and negative MACD). Corporate events provide only partial support via improved liquidity from financing, but operational uncertainty from halting clinical activity offsets that benefit, while valuation offers limited support given a loss-driven negative P/E and no dividend.
Positive Factors
Debt-Free Balance Sheet
No debt limits interest and refinancing risk, giving the company greater flexibility while it evaluates strategic alternatives. This financial structure is supportive over the next several months, although it does not eliminate the need to fund ongoing losses.
Negative Factors
Pre-Revenue Business
The absence of revenue leaves the company dependent on financing or strategic transactions to support operations. Persistent losses also indicate that there is no demonstrated commercial engine yet, making the investment case reliant on future clinical or partnering success.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
No debt limits interest and refinancing risk, giving the company greater flexibility while it evaluates strategic alternatives. This financial structure is supportive over the next several months, although it does not eliminate the need to fund ongoing losses.
Read all positive factors
Indaptus Therapeutics (INDP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$142.57M
Dividend YieldN/A
Average Volume (3M)1.08M
Price to Earnings (P/E)―
Beta (1Y)1.72
Revenue GrowthN/A
EPS Growth81.43%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.45
Shares Outstanding133,242,320
10 Day Avg. Volume869,867
30 Day Avg. Volume1,084,648
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.89
Price to Sales (P/S)0.00
P/FCF Ratio-0.19
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.34
Revenue Forecast (FY)N/A
Indaptus Therapeutics Business Overview & Revenue Model
Company Description
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compou...
How the Company Makes Money
null...
Indaptus Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -15.45M | -20.85M | -15.02M | -15.42M | -14.32M | -7.71M |
| Net Income | -15.42M | -20.85M | -15.02M | -15.42M | -14.32M | -7.71M |
Balance Sheet | ||||||
| Total Assets | 11.99M | 9.31M | 7.34M | 14.92M | 28.06M | 40.58M |
| Cash, Cash Equivalents and Short-Term Investments | 11.55M | 8.51M | 5.79M | 13.36M | 26.43M | 39.13M |
| Total Debt | 0.00 | 0.00 | 84.16K | 175.05K | 80.49K | 169.33K |
| Total Liabilities | 615.43K | 6.16M | 3.39M | 2.85M | 3.43M | 4.68M |
| Stockholders Equity | 11.37M | 3.15M | 3.94M | 12.08M | 24.63M | 35.90M |
Cash Flow | ||||||
| Free Cash Flow | -15.18M | -14.82M | -12.32M | -13.41M | -13.25M | -11.29M |
| Operating Cash Flow | -15.18M | -14.82M | -12.32M | -13.41M | -13.08M | -11.29M |
| Investing Cash Flow | -4.00M | 0.00 | 0.00 | 17.14M | -16.43M | 447.75K |
| Financing Cash Flow | 20.58M | 17.54M | 4.75M | 0.00 | 0.00 | 48.34M |
Indaptus Therapeutics Technical Analysis
Negative
2.61
Price Trends
2.47
Negative
2.31
Negative
2.30
Negative
Market Momentum
-0.41
Positive
27.73
Positive
9.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INDP, the sentiment is Negative. The current price of 2.61 is above the 20-day moving average (MA) of 1.59, above the 50-day MA of 2.47, and above the 200-day MA of 2.30, indicating a bearish trend. The MACD of -0.41 indicates Positive momentum. The RSI at 27.73 is Positive, neither overbought nor oversold. The STOCH value of 9.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INDP.
Indaptus Therapeutics Risk Analysis
Indaptus Therapeutics disclosed 65 risk factors in its most recent earnings report. Indaptus Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Indaptus Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $205.08M | -2.65 | -91.60% | ― | 3472.96% | 67.74% | |
46 Neutral | $227.61M | -4.83 | -94.14% | ― | -0.11% | -13.99% | |
46 Neutral | $128.94M | -1.66 | 44.63% | ― | 3.03% | 57.71% | |
44 Neutral | $142.57M | -0.18 | -302.75% | ― | ― | 81.43% | |
44 Neutral | $166.89M | -1.55 | -39.64% | ― | ― | -6.70% | |
44 Neutral | $52.79M | -0.86 | -108.72% | ― | 2.15% | 17.34% |
* Healthcare Sector Average
INDP
Indaptus Therapeutics
1.00
-6.76
-87.11%
CLLS
Cellectis SA
3.11
0.21
7.24%
DTIL
Precision BioSciences
7.40
2.45
49.49%
ADCT
ADC Therapeutics
1.10
-2.14
-66.05%
NKTX
Nkarta
2.43
0.08
3.40%
TCRX
TScan Therapeutics
0.78
-1.01
-56.26%
Indaptus Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingShareholder Meetings
Indaptus Therapeutics Reports Q2 Results Amid Strategic Pivot
Negative
Aug 13, 2026
Indaptus Therapeutics held its 2026 annual meeting of stockholders on August 10, 2026, where shareholders elected three Class II directors for terms running to 2029, ratified Haskell White LLP as independent auditor for 2026 and approved a new eq...
Private Placements and FinancingRegulatory Filings and Compliance
Indaptus Therapeutics Announces Private Placement of Common Stock
Positive
Jun 24, 2026
On June 17, 2026, Indaptus Therapeutics, Inc. entered into a Stock Purchase Agreement with certain non-U.S. accredited investors to sell 20,000,000 shares of its common stock at $0.60 per share in a private placement, raising approximately $12 mil...
Executive/Board Changes
Indaptus Therapeutics Announces Recent Board and Leadership Changes
Neutral
Jun 5, 2026
Indaptus Therapeutics, Inc. announced leadership changes effective June 2026, with directors David E. Lazar and Avraham Ben‑Tzvi resigning from all board and committee roles as of June 5, 2026. The company also reported that Chief Operating ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.